Portal
Portal Biotechnologies offers a microfluidic Cell Squeeze® platform that delivers diverse cargos—including proteins, RNPs, and mRNA—into any cell type without viral vectors or electroporation. The technology supports high-throughput CRISPR screens, multiplexed gene editing, and engineered red blood cell applications for immune modulation. It is used by over 100 customers across biopharma and academic research for drug discovery and cell therapy development.
- Biotechnology
- Drug Discovery & Therapeutics
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Conventional intracellular delivery methods such as viral vectors and electroporation are limited by cargo compatibility, cell-type restrictions, and safety concerns. These constraints impede research into impermeable molecules, complicate primary cell engineering, and slow the development of next-generation cell therapies.
Solution
Portal Biotechnologies offers a universal delivery platform that mechanically squeezes cells through microfluidic channels to create transient membrane disruptions, allowing diverse cargos to enter the cytoplasm without viral or electrical methods. The approach supports delivery of proteins, RNPs, mRNA, and other impermeable probes into hard-to-transfect cells including primary cells, immune cells, and iPSCs. This enables direct-to-biology assays, high-throughput CRISPR screens, and multiplexed genetic modifications while preserving cell viability and function. The platform is designed to accelerate research workflows and support scalable manufacturing of engineered cell therapies.
Target Audience
Primary customers are biopharmaceutical companies, academic research centers, and cell therapy developers seeking efficient intracellular delivery for drug discovery, functional genomics, and therapeutic cell engineering.
Features
- Microfluidic Cell Squeeze® technology enabling cytosolic delivery of proteins, RNPs, mRNA, and other impermeable cargos
- Compatible with a broad range of cell types including primary cells, immune cells, red blood cells, and iPSCs
- Supports high-throughput CRISPR screens and multiplexed modifications without viral vectors or electroporation
- Enables engineered red blood cell applications for antigen delivery and immune modulation
- Validated through peer-reviewed publications demonstrating T cell activation, antigen-specific tolerance, and antitumor responses
- Platform supports both "Ask Your Cell" workflows for research assays and "Design Your Cell" workflows for therapeutic engineering